Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030

icon1
USD 3.51 BN
MARKET SIZE,
icon2
CAGR 5.2%
(2025-2030)
icon3
317
REPORT PAGES
icon4
312
MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global veterinary biologics market is projected to reach USD 3.51 billion by 2030 from USD 2.72 billion in 2025, growing at a CAGR of 5.2% during the forecast period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention. Moreover, with the growing prevalence of zoonotic diseases and a stronger focus on food safety, the use of veterinary biologics is becoming essential for both livestock management and caring for companion animals.

KEY TAKEAWAYS

  • BY PRODUCT TYPE
    By product type, the market is segmented into monoclonal antibodies, immunoglobulins & antitoxins, immunomodulators & immunostimulants, and diagnostic kits. Monoclonal antibodies represent the leading product segment, driven by their precision, strong therapeutic efficacy, and rising use in managing both infectious and chronic diseases in animals. Their ability to deliver targeted treatment with minimal side effects makes them highly preferred over traditional therapies.
  • BY ANIMAL TYPE
    By animal type, the market is segmented into companion animals and livestock animals. The companion animals segment accounts for a larger market share, driven by the rising global pet population, increasing awareness about preventive healthcare, and early disease diagnosis in pets such as dogs and cats, which is boosting demand for advanced biologics. Additionally, the surge in zoonotic disease concerns has accelerated the adoption of biologics to protect both pet and human health safety.
  • BY ROUTE OF ADMINISTRATION
    By route of administration, the market is segmented into injectable route of administration, oral route of administration, and other routes of administration. The injectable segment held the largest market share due to its high efficacy, quick onset of action, and accurate dosing. Injectable biologics are commonly used in both livestock and companion animals to prevent and treat infectious diseases. The segment’s growth is further boosted by advancements in needle-free injection technologies and the increasing emphasis on disease control programs in veterinary care.
  • BY APPLICATION
    By application, the market is divided into infectious disease prevention, dermatology, oncology, pain management, diagnostic testing, and other applications. The dermatology segment holds the largest share of the veterinary biologics market, driven by the increasing prevalence of skin infections and allergies among companion animals. Growing awareness about pet health, along with the rising demand for advanced biologic therapies for conditions like dermatitis, further boosts this segment growth.
  • BY END USER
    By end user, the market is segmented into veterinary hospitals & clinics, veterinary diagnostic labs, and other end users. The veterinary hospitals and clinics segment held the largest market share, driven by the rising number of companion animals, increased awareness of preventive healthcare, and growing demand for specialized biologics and vaccines. Hospitals and clinics provide professional administration of biologics, ensuring proper dosing, safety, and effectiveness, which further boosts the segment’s dominance.
  • BY REGION
    The North American region is expected to witness the highest growth in the veterinary biologics market during the forecast period. This growth is driven by the increasing companion population, and growing awareness of animal health and disease prevention. Additionally, favorable government initiatives, investments in veterinary healthcare infrastructure, and the early approval and adoption of advanced biologics in US and Canada are fueling market expansion in the region.
  • COMPETITIVE LANDSCAPE
    The major market players have adopted both organic and inorganic strategies, including partnerships and collaborations. For instance, in September 2024, Zoetis Services LLC (US) partnered with the Arthritis Foundation (US) to raise awareness about osteoarthritis (OA) pain in pets. Through this partnership, Zoetis highlights Librela, its FDA-approved, once-monthly injectable monoclonal antibody for dogs, as a breakthrough therapy for managing OA pain, promoting better mobility and quality of life.

The veterinary biologics market is expected to grow significantly in the coming years, fueled by the expanding populations of livestock and pets and the increasing demand for effective animal health solutions. As infectious diseases become more common and awareness of preventive healthcare rises, livestock farms and veterinary clinics are increasingly adopting biologics to improve animal health, productivity, and food safety. Supportive government policies, higher investments in veterinary healthcare infrastructure, and the focus on disease prevention and biosecurity further boost the market, making veterinary biologics a vital part of modern animal health management.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The veterinary biologics market is shifting from traditional biologics like monoclonal antibodies, antisera, and immunomodulators toward smarter, more connected solutions. While current revenue mainly depends on one-time product sales, the future emphasizes data-driven delivery systems, personalized dosing, and IoT-enabled monitoring as key growth drivers. Veterinary clients, including pharmaceutical companies, specialty clinics, and livestock managers, prioritize regulatory compliance, enhanced therapeutic accuracy, remote monitoring support, and streamlined biologics administration. These efforts lead to better outcomes for animals, such as improved health, safer treatments, quicker interventions, and personalized care plans, while also lowering costs and operational complexity.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Surge in companion animal population and pet ownership
  • Increasing incidence of infectious zoonotic diseases
RESTRAINTS
Impact
Level
  • High cost of veterinary diagnostic tests
  • Regulatory hurdles and long approval timelines
OPPORTUNITIES
Impact
Level
  • Untapped growth potential in emerging economies
  • Evolving landscape of strategic collaborations and acquisitions
CHALLENGES
Impact
Level
  • Limited awareness and shortage of trained veterinarians in low-income countries
  • Stringent regulatory requirements for licensing veterinary biologics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Surge in companion animal population and pet ownership

Urbanization and evolving lifestyles have significantly boosted pet ownership across the globe, especially in countries like India, Brazil, and the United States. This trend is fueled by increasing disposable incomes, the desire for emotional companionship, and changing perceptions of pets as family members. As a result, there is higher spending on preventive care and wellness, which in turn drives demand for veterinary treatments and products such as diagnostic kits, monoclonal antibody therapies, and immunomodulatory treatments that are crucial for pet health. The worldwide population of companion animals, including dogs and cats, has grown substantially in both developed areas like North America and emerging markets such as India and China. According to the 2023-2024 National Pet Owners Survey by the American Pet Products Association, about 66% of American households—approximately 86.9 million—own a pet, further fueling growth in the veterinary biologics sector and the larger pet care market.

Restraint: High cost of veterinary diagnostic tests

The high cost of advanced diagnostic tests and imaging systems poses a significant obstacle to adopting veterinary diagnostics. In the US, public health spending on rabies diagnostics, prevention, and control ranges from USD 245 million to 510 million annually, covering vaccination, testing, and biologics for rabies prevention, although the total expense, including healthcare and animal control, is even higher. Veterinary diagnostic imaging equipment is also expensive, with portable devices costing between USD 2,000 and 50,000, and additional accessories such as transducer probes and printers increasing costs. Since most veterinary practices are small or medium-sized with limited budgets, these high expenses, combined with the lack of reimbursement for veterinary procedures, considerably limit the growth and adoption of veterinary biologics in the market.

Opportunity: Evolving landscape of strategic collaborations and acquisitions

The veterinary biologics market is gaining momentum amid a rapidly evolving landscape of strategic partnerships and acquisitions. Market players are increasingly forming synergistic collaborations to boost innovation, diversify therapeutic options, and expand globally. These changes are reshaping the competitive environment and opening new therapeutic areas and delivery platforms in animal health. One of the most notable moves in this market is Dechra Pharmaceuticals' acquisition of Invetx in July 2024. This acquisition reflects Dechra’s strategic goal to go beyond traditional small-molecule therapies and focus more on chronic and complex diseases in companion animals, such as osteoarthritis, inflammation, and dermatological issues.

Challenge: Stringent regulatory requirements for licensing veterinary biologics

The veterinary biologics market is heavily influenced by strict regulatory frameworks that govern the development, testing, approval, and distribution of products like antitoxins and monoclonal antibodies. Agencies such as the USDA (Center for Veterinary Biologics), EMA, and other national authorities require comprehensive safety, efficacy, and quality data before granting approvals. These standards often involve lengthy clinical trials, detailed documentation, and significant investment in quality assurance systems, making product development slow and expensive. Additionally, the lack of unified regulatory standards across countries complicates global commercialization. Manufacturers must navigate different approval processes in each region, which increases compliance costs and delays product launches.

Veterinary Biologics Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Development and commercialization of monoclonal antibody therapies for pets Targeted treatments for chronic conditions like osteoarthritis, fewer side effects
Immunomodulatory therapies and dermatology-related biologics for companion animals Long-lasting allergy relief, improved immune regulation
Biologics targeting chronic inflammatory and parasitic diseases Better disease control, increased pet quality of life
Development of novel biologics for companion animals focusing on chronic diseases Enhances quality of life, extends lifespan, personalized treatment options
Diagnostic testing kits and platforms for early disease detection Early diagnosis, preventive care, improved treatment outcomes

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The veterinary biologics market ecosystem comprises a complex network of stakeholders, including manufacturers of diagnostic kits, monoclonal antibodies, and antitoxins, along with research institutions, regulatory authorities, distributors, veterinary healthcare providers, and end users such as clinics, hospitals, diagnostic labs, and government agencies. Innovation is fueled by R&D collaborations, advances in biotechnology, and rising demand for preventive animal healthcare. Regulatory agencies ensure safety and compliance, while distribution partners are vital for market access and cold chain logistics. This interconnected ecosystem is influenced by disease prevalence, trends in livestock and pet populations, and evolving animal health policies across regions.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Veterinary Biologics Market, By Product Type

In the veterinary biologics market, monoclonal antibodies hold the largest market share by product type because of their high specificity, effectiveness, and rising use in treating infectious and chronic conditions in animals. These biologics provide targeted therapy with fewer side effects compared to traditional drugs, leading to better treatment outcomes. Increasing R&D investments, regulatory approvals, and the broader application of monoclonal antibodies in both livestock and companion animals further strengthen their market dominance.

Veterinary Biologics Market, By Animal Type

In the veterinary biologics market, the livestock segment held a significant share due to high demand for diagnostics and immunological products that ensure herd health and productivity. Livestock such as cattle, poultry, and swine are essential for global food supply chains, making disease prevention and control a top priority. Rising meat and dairy consumption, along with government initiatives to curb zoonotic diseases and economic losses from outbreaks, further reinforce the dominance of livestock biologics over companion animal applications.

Veterinary Biologics Market, By Route of Administration

The injectable segment is expected to grow the fastest in the veterinary biologics market, driven by its effectiveness in providing quick and targeted immune responses. Injectables remain the preferred method for administering monoclonal antibodies and therapeutic biologics due to their higher bioavailability and controlled dosing. Rising demand for preventive care in livestock, especially against infectious diseases, is increasing the adoption of injectables. In companion animals, injectables are commonly used for dermatology and chronic disease management, further boosting their use. Additionally, ongoing innovations in long-acting injectables and combination biologics are enhancing treatment convenience and adherence. The strong pipeline of injectable veterinary biologics and expanding regulatory approvals are likely to accelerate market growth.

Veterinary Biologics Market, By Application

The dermatology segment held the largest share in the veterinary biologics market, driven by the high prevalence of chronic skin conditions in companion animals. The introduction of monoclonal antibody-based biologics targeting chronic skin diseases has further boosted this segment’s growth. Additionally, rising pet ownership, increasing awareness of animal health, and pet owners' greater willingness to spend on advanced therapies are fueling adoption. Furthermore, ongoing product innovations are improving accessibility and supporting market growth.

Veterinary Biologics Market, By End User

In the veterinary biologics market, veterinary hospitals and clinics hold the largest share by end user because they serve as the primary point of care for both companion animals and livestock. These facilities are the main channels for delivering diagnostics and advanced biologic therapies, supported by well-trained veterinary professionals and established infrastructure. The growing pet population, increased awareness of preventive healthcare, and rising expenditure on animal health further reinforce the dominance of hospitals and clinics in this segment.

REGION

North America is expected to be the fastest-growing region in the global veterinary biologics market during the forecast period.

North America is the fastest-growing region in the veterinary biologics market, fueled by the prominent presence of leading companies, strong R&D efforts, and widespread use of advanced monoclonal antibody therapies for companion animals. Additionally, rising pet ownership, a well-established veterinary infrastructure, and favorable reimbursement policies drive the adoption of high-cost biologics. Moreover, the increasing prevalence of zoonotic diseases and chronic conditions in animals is boosting the demand for targeted biologic treatments. Ongoing regulatory approvals and strategic collaborations among biopharma companies continue to support market growth.

Veterinary Biologics Market: COMPANY EVALUATION MATRIX

In the veterinary biologics market matrix, Zoetis Services LLC (Star) leads with scale, widespread distribution, and a broad solutions portfolio. Bio-Rad Laboratories, Inc. (Emerging Leader) is gaining momentum with innovative diagnostic kits. While Zoetis dominates through extensive reach, Bio-Rad's innovation positions it for rapid growth toward the leaders’ quadrant.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 2.61 Billion
Market Forecast in 2030 (Value) USD 3.51 Billion
Growth Rate CAGR of 5.2% from 2025-2030
Years Considered 2023–2030
Base Year 2024
Forecast Period 2025–2030
Units Considered Value (USD Million/Billion), Volume (Thousand units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  •   By product type:
    • Monoclonal Antibodies
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Diagnostic Kits
  • By Animal Type:
    • companion animals
    • livestock animals
  • By route of administration:
    • Injectable
    • oral
    • other routes of administration
  • By Application:
    • Infectious Diseases Prevention
    • Dermatology
    • Oncology
    • Pain Management
    • Diagnostic Testing
    • Other Applications
  • By End User:
    • Veterinary Hospitals & Clinics
    • Veterinary Diagnostic Labs
    • Other End Users
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: Veterinary Biologics Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Product Analysis Comparison of key veterinary biologics categories: monoclonal antibodies, Antisera, immunomodulators, and diagnostic kits Identify biologic use-cases across species, storage/supply risks, and regulatory nuances
Company Information Zoetis, Boehringer Ingelheim, Elanco, Merck Animal Health. Market share analysis of top 3–5 players in ASEAN & Europe Competitive analysis for biologics portfolios, outsourcing trends in diagnostics & biologics, and localization strategies
Geographic Analysis Detailed analysis for the Rest of Asia Pacific; the client is focused on ASEAN countries for country-level Veterinary Biologics market insights Demand mapping for diagnostics and therapeutic biologics, local partnership potential, and biologics-specific regulatory assessment

RECENT DEVELOPMENTS

  • May 2025 : Zoetis Services LLC opened its largest diagnostics reference laboratory at the UPS Healthcare Labport in Louisville, Kentucky. This 32,000 sq. ft. facility, near UPS Worldport, enables rapid specimen processing and quicker diagnostic results for veterinarians across the country. The lab represents a major milestone in Zoetis Services LLC's dedication to advancing diagnostic services and improving animal care through cutting-edge technology, logistics, and expertise teams.
  • October 2024 : Merck & Co., Inc. launched Gilvetmab (gil-VET-mab), a caninized monoclonal antibody for oncology-practicing veterinary specialists across the US. Gilvetmab previously received conditional license approval from the USDA Center for Veterinary Biologics (CVB) to treat dogs with mast cell tumors and melanoma.
  • May 2023 : Zoetis Services LLC received FDA approval for Librela (bedinvetmab), the first and only monthly injectable monoclonal antibody targeting nerve growth factor (NGF) to control osteoarthritis pain in dogs. It offers lasting improvements in mobility and quality of life, as validated by clinical trials involving client-owned pets.
  • May 2023 : Elanco introduced the first USDA conditionally approved monoclonal antibody treatment for canine parvovirus, a highly contagious and often deadly disease in puppies.

 

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
TABLE OF CONTENTS
 
 
 
 
 
1
INTRODUCTION
 
 
 
29
2
RESEARCH METHODOLOGY
 
 
 
33
3
EXECUTIVE SUMMARY
 
 
 
47
4
PREMIUM INSIGHTS
 
 
 
52
5
MARKET OVERVIEW
Surging pet ownership and zoonotic disease innovations drive veterinary market growth amid regulatory challenges.
 
 
 
57
 
5.1
INTRODUCTION
 
 
 
 
5.2
MARKET DYNAMICS
 
 
 
 
 
5.2.1
DRIVERS
 
 
 
 
 
5.2.1.1
Surge in companion animal population and pet ownership
 
 
 
 
5.2.1.2
Increasing incidence of infectious zoonotic diseases
 
 
 
 
5.2.1.3
Innovations in monoclonal antibodies targeting infectious diseases
 
 
 
 
5.2.1.4
Supportive initiatives by government agencies and animal health organizations
 
 
 
 
5.2.1.5
Rising demand for animal-derived food products
 
 
 
5.2.2
RESTRAINTS
 
 
 
 
 
5.2.2.1
High cost of veterinary diagnostic tests
 
 
 
 
5.2.2.2
Regulatory hurdles and long approval timelines
 
 
 
 
5.2.2.3
Rising pet care costs
 
 
 
5.2.3
OPPORTUNITIES
 
 
 
 
 
5.2.3.1
Evolving landscape of strategic collaborations and acquisitions
 
 
 
 
5.2.3.2
Untapped growth potential in emerging economies
 
 
 
5.2.4
CHALLENGES
 
 
 
 
 
5.2.4.1
Limited awareness and shortage of trained veterinarians in low-income countries
 
 
 
 
5.2.4.2
Stringent regulatory requirements for licensing veterinary biologics
 
 
5.3
TECHNOLOGY ANALYSIS
 
 
 
 
 
5.3.1
KEY TECHNOLOGIES
 
 
 
 
 
5.3.1.1
Hybridoma technology
 
 
 
 
5.3.1.2
Biosensor-based diagnostic systems
 
 
 
5.3.2
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
5.3.2.1
Long-acting injectables
 
 
 
 
5.3.2.2
Next-generation sequencing
 
 
 
5.3.3
ADJACENT TECHNOLOGIES
 
 
 
 
 
5.3.3.1
Wearable biosensors & remote monitoring devices
 
 
5.4
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
5.5
VALUE CHAIN ANALYSIS
 
 
 
 
 
5.6
TRADE ANALYSIS
 
 
 
 
 
 
5.6.1
IMPORT DATA FOR HS CODE 300214, 2021–2024
 
 
 
 
5.6.2
EXPORT DATA FOR HS CODE 300214, 2021–2024
 
 
 
5.7
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
5.7.1
THREAT OF NEW ENTRANTS
 
 
 
 
5.7.2
THREAT OF SUBSTITUTES
 
 
 
 
5.7.3
BARGAINING POWER OF SUPPLIERS
 
 
 
 
5.7.4
BARGAINING POWER OF BUYERS
 
 
 
 
5.7.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
5.8
KEY STAKEHOLDERS & BUYING CRITERIA
 
 
 
 
 
 
5.8.1
KEY STAKEHOLDERS IN BUYING PROCESS
 
 
 
 
5.8.2
KEY BUYING CRITERIA
 
 
 
5.9
REGULATORY ANALYSIS
 
 
 
 
 
5.9.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
5.9.2
REGULATORY FRAMEWORK
 
 
 
 
 
5.9.2.1
North America
 
 
 
 
5.9.2.2
Europe
 
 
 
 
5.9.2.3
Asia Pacific
 
 
 
 
5.9.2.4
Latin America
 
 
 
 
5.9.2.5
Middle East & Africa
 
 
5.10
PATENT ANALYSIS
 
 
 
 
 
 
5.10.1
PATENT PUBLICATION TREND
 
 
 
 
5.10.2
JURISDICTION AND TOP APPLICANT ANALYSIS
 
 
 
 
5.10.3
INNOVATIONS AND PATENT REGISTRATIONS
 
 
 
5.11
PRICING ANALYSIS
 
 
 
 
 
 
5.11.1
INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024
 
 
 
 
5.11.2
INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022–2024
 
 
 
5.12
KEY CONFERENCES & EVENTS, 2025–2026
 
 
 
 
5.13
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
5.13.1
ROLE IN ECOSYSTEM
 
 
 
5.14
REIMBURSEMENT ANALYSIS
 
 
 
 
5.15
UNMET NEEDS
 
 
 
 
5.16
IMPACT OF AI/GEN AI ON VETERINARY BIOLOGICS MARKET
 
 
 
 
 
 
5.16.1
POTENTIAL OF AI IN VETERINARY BIOLOGICS
 
 
 
 
5.16.2
AI USE CASES
 
 
 
 
5.16.3
KEY COMPANIES IMPLEMENTING AI
 
 
 
5.17
INVESTMENT & FUNDING SCENARIO
 
 
 
 
 
5.18
PIPELINE ANALYSIS
 
 
 
 
5.19
IMPACT OF 2025 US TARIFF ON VETERINARY BIOLOGICS MARKET
 
 
 
 
 
 
5.19.1
INTRODUCTION
 
 
 
 
5.19.2
KEY TARIFF RATES
 
 
 
 
5.19.3
PRICE IMPACT ANALYSIS
 
 
 
 
5.19.4
IMPACT ON COUNTRY/REGION
 
 
 
 
5.19.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
5.19.5.1
Veterinary hospitals & clinics
 
 
 
 
5.19.5.2
Veterinary diagnostic labs
 
 
 
 
5.19.5.3
Other end users
 
6
VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 8 Data Tables
 
 
 
97
 
6.1
INTRODUCTION
 
 
 
 
6.2
MONOCLONAL ANTIBODIES
 
 
 
 
 
6.2.1
INCREASED PET OWNERSHIP AND HUMANIZATION TO RAISE HEALTH AWARENESS AND SPENDING ON ANTIBODY THERAPIES
 
 
 
6.3
IMMUNOGLOBULINS & ANTITOXINS
 
 
 
 
 
6.3.1
INCREASED PREVALENCE OF ZOONOTIC AND TOXIN-MEDIATED DISEASES TO FUEL MARKET GROWTH
 
 
 
6.4
IMMUNOMODULATORS & IMMUNOSTIMULANTS
 
 
 
 
 
6.4.1
IMMUNOMODULATORS & IMMUNOSTIMULANTS TO CORRECT IMMUNE DYSFUNCTIONS AND CONTROL OVERACTIVE IMMUNE CONDITIONS
 
 
 
6.5
DIAGNOSTIC KITS
 
 
 
 
 
6.5.1
DIAGNOSTIC KITS TO IMPROVE DISEASE SURVEILLANCE AND MANAGEMENT IN COMPANION ANIMALS, LIVESTOCK, AND POULTRY
 
 
7
VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 20 Data Tables
 
 
 
106
 
7.1
INTRODUCTION
 
 
 
 
7.2
COMPANION ANIMALS
 
 
 
 
 
7.2.1
CANINE
 
 
 
 
 
7.2.1.1
Widespread ownership of pet dogs to generate consistent demand for preventive care and advanced biologics
 
 
 
7.2.2
FELINE
 
 
 
 
 
7.2.2.1
Rising pet cat population and increasing feline diseases to propel market growth
 
 
7.3
LIVESTOCK ANIMALS
 
 
 
 
 
7.3.1
BOVINE
 
 
 
 
 
7.3.1.1
Need for better herd healthcare and introduction of antibody-based biologics to fuel segment growth
 
 
 
7.3.2
SMALL RUMINANT
 
 
 
 
 
7.3.2.1
Increasing global demand for sheep & goat meat and expanding herd size to boost market growth
 
 
 
7.3.3
PORCINE
 
 
 
 
 
7.3.3.1
Innovation in monoclonal antibodies for infectious diseases to drive market
 
 
 
7.3.4
POULTRY
 
 
 
 
 
7.3.4.1
Rising frequency of poultry diseases to augment market growth for better poultry health and improved food security
 
 
 
7.3.5
EQUINE
 
 
 
 
 
7.3.5.1
Equestrian sports, recreational riding, and managing failure of passive transfer (FPT) in foals to drive market
 
8
VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 9 Data Tables
 
 
 
125
 
8.1
INTRODUCTION
 
 
 
 
8.2
INJECTABLE ROUTE OF ADMINISTRATION
 
 
 
 
 
8.2.1
SUBCUTANEOUS ROUTE OF ADMINISTRATION
 
 
 
 
 
8.2.1.1
Ease of administration, reduced pain, and lower risk of tissue damage to aid market growth
 
 
 
8.2.2
INTRAMUSCULAR ROUTE OF ADMINISTRATION
 
 
 
 
 
8.2.2.1
Better immune response and lower rate of injection-site reactions to fuel market growth
 
 
 
8.2.3
INTRAVENOUS ROUTE OF ADMINISTRATION
 
 
 
 
 
8.2.3.1
Rapid action and targeted therapy to drive adoption of intravenous biologics
 
 
 
8.2.4
OTHER INJECTABLE ROUTES OF ADMINISTRATION
 
 
 
8.3
ORAL ROUTE OF ADMINISTRATION
 
 
 
 
 
8.3.1
EASE OF ADMINISTRATION AND COST-EFFECTIVENESS TO FOCUS ON LARGE-SCALE, NON-INVASIVE ORAL DELIVERY
 
 
 
8.4
OTHER ROUTES OF ADMINISTRATION
 
 
 
9
VETERINARY BIOLOGICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 7 Data Tables
 
 
 
138
 
9.1
INTRODUCTION
 
 
 
 
9.2
DERMATOLOGY
 
 
 
 
 
9.2.1
PREVALENCE OF CHRONIC SKIN CONDITIONS TO AUGMENT VETERINARY DERMATOLOGY MARKET GROWTH
 
 
 
9.3
DIAGNOSTIC TESTING
 
 
 
 
 
9.3.1
RISING PREVALENCE OF ZOONOTIC AND VIRAL DISEASES TO INCREASE DEMAND FOR BIOLOGIC-BASED DIAGNOSTIC TOOLS
 
 
 
9.4
PAIN MANAGEMENT
 
 
 
 
 
9.4.1
NEED FOR NON-OPIOID, SIDE-EFFECT-FREE PAIN SOLUTIONS AMONG PET OWNERS TO DRIVE MARKET
 
 
 
9.5
INFECTIOUS DISEASE PREVENTION
 
 
 
 
 
9.5.1
RISING INCIDENCE OF ZOONOTIC DISEASES AND ACUTE INFECTIONS TO ACCELERATE USE OF VETERINARY BIOLOGICS
 
 
 
9.6
ONCOLOGY
 
 
 
 
 
9.6.1
FOCUS ON IMMUNE-TARGETED CONTROL OF AGGRESSIVE CANCEROUS TUMORS TO AID MARKET GROWTH
 
 
 
9.7
OTHER APPLICATIONS
 
 
 
10
VETERINARY BIOLOGICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 5 Data Tables
 
 
 
148
 
10.1
INTRODUCTION
 
 
 
 
10.2
VETERINARY HOSPITALS & CLINICS
 
 
 
 
 
10.2.1
INCREASE IN VETERINARY SPECIALISTS AND RISE IN PET OWNERSHIP TO PROPEL MARKET GROWTH
 
 
 
10.3
VETERINARY DIAGNOSTIC LABS
 
 
 
 
 
10.3.1
VETERINARY DIAGNOSTIC LABS TO BECOME ESSENTIAL IN DISEASE DETECTION WITH PREVENTIVE BIOLOGIC INTERVENTIONS
 
 
 
10.4
OTHER END USERS
 
 
 
11
VETERINARY BIOLOGICS MARKET, BY REGION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million and Units | 172 Data Tables
 
 
 
154
 
11.1
INTRODUCTION
 
 
 
 
11.2
NORTH AMERICA
 
 
 
 
 
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
 
 
 
 
11.2.2
US
 
 
 
 
 
11.2.2.1
US to dominate North American veterinary biologics market during forecast period
 
 
 
11.2.3
CANADA
 
 
 
 
 
11.2.3.1
Ongoing developments in veterinary monoclonal antibodies and increasing animal health expenditure to fuel market growth
 
 
11.3
EUROPE
 
 
 
 
 
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
 
 
 
 
11.3.2
GERMANY
 
 
 
 
 
11.3.2.1
Established veterinary infrastructure and innovation funding to provide favorable environment for biologics adoption
 
 
 
11.3.3
UK
 
 
 
 
 
11.3.3.1
Strong regulatory framework and high pet population to boost market growth
 
 
 
11.3.4
FRANCE
 
 
 
 
 
11.3.4.1
Increase in companion animal health spending by pet owners to propel market growth
 
 
 
11.3.5
ITALY
 
 
 
 
 
11.3.5.1
Better availability of pet products through large-scale outlets to augment market growth
 
 
 
11.3.6
SPAIN
 
 
 
 
 
11.3.6.1
Increased pet population and favorable government regulations to drive market
 
 
 
11.3.7
NETHERLANDS
 
 
 
 
 
11.3.7.1
Focus on meat export to positively influence veterinary biologics market
 
 
 
11.3.8
REST OF EUROPE
 
 
 
11.4
ASIA PACIFIC
 
 
 
 
 
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
 
 
 
 
11.4.2
JAPAN
 
 
 
 
 
11.4.2.1
Growing consumption of animal-derived products to propel market growth
 
 
 
11.4.3
CHINA
 
 
 
 
 
11.4.3.1
Large pool of food-producing animals and high companion animal ownership to propel market growth
 
 
 
11.4.4
INDIA
 
 
 
 
 
11.4.4.1
Rising demand for dairy products to fuel market growth
 
 
 
11.4.5
AUSTRALIA
 
 
 
 
 
11.4.5.1
Rise in pet ownership to support increased spending on veterinary care
 
 
 
11.4.6
SOUTH KOREA
 
 
 
 
 
11.4.6.1
Expanding pet care industry and increasing chronic veterinary diseases to drive market
 
 
 
11.4.7
NEW ZEALAND
 
 
 
 
 
11.4.7.1
Increased pet ownership and demand for advanced veterinary treatments to drive market
 
 
 
11.4.8
REST OF ASIA PACIFIC
 
 
 
11.5
LATIN AMERICA
 
 
 
 
 
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
 
 
 
 
11.5.2
BRAZIL
 
 
 
 
 
11.5.2.1
Large-scale livestock operations and strong veterinary infrastructure to drive market
 
 
 
11.5.3
MEXICO
 
 
 
 
 
11.5.3.1
Increasing demand for targeted biologics in livestock and pets to drive market growth
 
 
 
11.5.4
REST OF LATIN AMERICA
 
 
 
11.6
MIDDLE EAST & AFRICA
 
 
 
 
 
11.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
 
 
 
 
11.6.2
GCC COUNTRIES
 
 
 
 
 
11.6.2.1
Kingdom of Saudi Arabia (KSA)
 
 
 
 
11.6.2.2
United Arab Emirates (UAE)
 
 
 
 
11.6.2.3
Rest of GCC Countries
 
 
 
11.6.3
REST OF MIDDLE EAST & AFRICA
 
 
12
COMPETITIVE LANDSCAPE
Uncover market dominance strategies of top veterinary biologics players and emerging startup dynamics.
 
 
 
230
 
12.1
INTRODUCTION
 
 
 
 
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
12.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET
 
 
 
12.3
REVENUE ANALYSIS, 2022–2024
 
 
 
 
 
12.4
MARKET SHARE ANALYSIS, 2024
 
 
 
 
 
 
12.4.1
VETERINARY BIOLOGICS MARKET SHARE ANALYSIS
 
 
 
 
12.4.2
US: VETERINARY BIOLOGICS MARKET SHARE ANALYSIS, 2024
 
 
 
 
12.4.3
VETERINARY DIAGNOSTICS KITS MARKET SHARE ANALYSIS
 
 
 
 
12.4.4
US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024
 
 
 
12.5
RANKING OF KEY PLAYERS
 
 
 
 
 
12.5.1
VETERINARY BIOLOGICS MARKET RANKING
 
 
 
 
12.5.2
VETERINARY DIAGNOSTIC KITS MARKET RANKING
 
 
 
12.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
 
 
 
 
 
 
12.6.1
STARS
 
 
 
 
12.6.2
EMERGING LEADERS
 
 
 
 
12.6.3
PERVASIVE PLAYERS
 
 
 
 
12.6.4
PARTICIPANTS
 
 
 
 
12.6.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
 
 
 
 
 
12.6.5.1
Company footprint
 
 
 
 
12.6.5.2
Region footprint
 
 
 
 
12.6.5.3
Product type footprint
 
 
 
 
12.6.5.4
Animal type footprint
 
 
 
 
12.6.5.5
Application footprint
 
 
12.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
 
 
 
 
 
 
12.7.1
PROGRESSIVE COMPANIES
 
 
 
 
12.7.2
RESPONSIVE COMPANIES
 
 
 
 
12.7.3
DYNAMIC COMPANIES
 
 
 
 
12.7.4
STARTING BLOCKS
 
 
 
 
12.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 
 
 
 
 
12.7.5.1
Detailed list of key startup/SMEs
 
 
 
 
12.7.5.2
Competitive benchmarking of key startups/SMEs
 
 
12.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
12.9
COMPANY VALUATION & FINANCIAL METRICS
 
 
 
 
 
12.9.1
FINANCIAL METRICS
 
 
 
 
12.9.2
COMPANY VALUATION
 
 
 
12.10
COMPETITIVE SCENARIO
 
 
 
 
 
12.10.1
PRODUCT LAUNCHES & APPROVALS
 
 
 
 
12.10.2
DEALS
 
 
 
 
12.10.3
EXPANSIONS
 
 
 
 
12.10.4
OTHER DEVELOPMENTS
 
 
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
256
 
13.1
KEY PLAYERS
 
 
 
 
 
13.1.1
ZOETIS SERVICES LLC
 
 
 
 
 
13.1.1.1
Business overview
 
 
 
 
13.1.1.2
Products offered
 
 
 
 
13.1.1.3
Recent developments
 
 
 
 
13.1.1.4
MnM view
 
 
 
13.1.2
IDEXX
 
 
 
 
13.1.3
ELANCO
 
 
 
 
13.1.4
MERCK & CO., INC.
 
 
 
 
13.1.5
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
13.1.6
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 
 
 
 
13.1.7
NEOGEN CORPORATION
 
 
 
 
13.1.8
BIO-RAD LABORATORIES, INC.
 
 
 
 
13.1.9
IMMUCELL CORPORATION
 
 
 
 
13.1.10
INNOVATIVE DIAGNOSTICS
 
 
 
13.2
OTHER PLAYERS
 
 
 
 
 
13.2.1
BIONOTE USA INC.
 
 
 
 
13.2.2
BIOCHEK
 
 
 
 
13.2.3
PLASVACC USA
 
 
 
 
13.2.4
NOVAVIVE INC.
 
 
 
 
13.2.5
MG BIOLOGICS
 
 
 
 
13.2.6
STALLERGENES GREER
 
 
 
 
13.2.7
BIOSTONE ANIMAL HEALTH
 
 
 
 
13.2.8
COLORADO SERUM COMPANY
 
 
 
 
13.2.9
PADULA SERUMS PTY LTD.
 
 
 
 
13.2.10
LAKE IMMUNOGENICS
 
 
 
 
13.2.11
INBIOS INTERNATIONAL, INC.
 
 
 
 
13.2.12
PRINCETON BIOMEDITECH CORPORATION
 
 
 
 
13.2.13
TETRACORE, INC.
 
 
 
 
13.2.14
VMRD, INC.
 
 
 
 
13.2.15
ANIMAB
 
 
14
APPENDIX
 
 
 
309
 
14.1
DISCUSSION GUIDE
 
 
 
 
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
14.3
AVAILABLE CUSTOMIZATIONS
 
 
 
 
 
14.3.1
GEOGRAPHIC ANALYSIS
 
 
 
 
14.3.2
REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS
 
 
 
 
14.3.3
COMPANY INFORMATION
 
 
 
 
14.3.4
PRODUCT ANALYSIS
 
 
 
 
14.3.5
COUNTRY-LEVEL VOLUME ANALYSIS
 
 
 
 
14.3.6
ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
 
 
 
 
14.3.7
BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
 
 
 
14.4
RELATED REPORTS
 
 
 
 
14.5
AUTHOR DETAILS
 
 
 
LIST OF TABLES
 
 
 
 
 
TABLE 1
VETERINARY BIOLOGICS MARKET: INCLUSIONS & EXCLUSIONS
 
 
 
 
TABLE 2
VETERINARY BIOLOGICS MARKET: STUDY ASSUMPTIONS
 
 
 
 
TABLE 3
VETERINARY BIOLOGICS MARKET: RISK ANALYSIS
 
 
 
 
TABLE 4
PET (DOGS AND CATS) OWNERSHIP AND SPENDING IN US, 2024
 
 
 
 
TABLE 5
MAJOR OUTBREAKS OF ZOONOTIC DISEASES, 2022–2025
 
 
 
 
TABLE 6
PAST AND PROJECTED TRENDS IN MEAT AND MILK CONSUMPTION IN DEVELOPED COUNTRIES, 2002 VS. 2015 VS. 2030 VS. 2050
 
 
 
 
TABLE 7
ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
 
 
 
 
TABLE 8
ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
 
 
 
 
TABLE 9
IMPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
TABLE 10
EXPORT DATA FOR HS CODE 300214, BY COUNTRY, 2021–2024 (USD THOUSAND)
 
 
 
 
TABLE 11
VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES
 
 
 
 
TABLE 12
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF VETERINARY BIOLOGICS, BY END USER
 
 
 
 
TABLE 13
KEY BUYING CRITERIA FOR END USERS
 
 
 
 
TABLE 14
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 15
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 16
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
TABLE 17
VETERINARY BIOLOGICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS OF VETERINARY MONOCLONAL ANTIBODIES, 2023–2024
 
 
 
 
TABLE 18
INDICATIVE PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY KEY PLAYER, 2024 (USD)
 
 
 
 
TABLE 19
INDICATIVE SELLING PRICE OF VETERINARY MONOCLONAL ANTIBODIES, BY REGION, 2022–2024 (USD)
 
 
 
 
TABLE 20
DETAILED LIST OF KEY CONFERENCES & EVENTS IN VETERINARY BIOLOGICS MARKET, JANUARY 2025–DECEMBER 2026
 
 
 
 
TABLE 21
VETERINARY BIOLOGICS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
TABLE 22
UNMET NEEDS IN VETERINARY BIOLOGICS MARKET
 
 
 
 
TABLE 23
KEY COMPANIES IMPLEMENTING AI IN VETERINARY BIOLOGICS MARKET
 
 
 
 
TABLE 24
PIPELINE ANALYSIS IN VETERINARY BIOLOGICS MARKET
 
 
 
 
TABLE 25
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
TABLE 26
KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR VETERINARY BIOLOGICS MARKET
 
 
 
 
TABLE 27
IMPACT OF US TARIFFS ON COUNTRIES/REGIONS
 
 
 
 
TABLE 28
VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 29
LIST OF COMMERCIALLY AVAILABLE MONOCLONAL ANTIBODIES
 
 
 
 
TABLE 30
VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 31
LIST OF USDA-APPROVED IMMUNOGLOBULINS & ANTITOXINS
 
 
 
 
TABLE 32
VETERINARY BIOLOGICS MARKET FOR IMMUNOGLOBULINS & ANTITOXINS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 33
VETERINARY BIOLOGICS MARKET FOR IMMUNOMODULATORS & IMMUNOSTIMULANTS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 34
LIST OF LICENSED VETERINARY DIAGNOSTIC KITS AS APPROVED BY US FDA CENTER FOR VETERINARY BIOLOGICS
 
 
 
 
TABLE 35
VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC KITS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 36
VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 37
COMPANION ANIMALS OWNERSHIP IN US, 2024
 
 
 
 
TABLE 38
VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 39
VETERINARY BIOLOGICS MARKET FOR COMPANION ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 40
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR CANINES
 
 
 
 
TABLE 41
VETERINARY BIOLOGICS MARKET FOR CANINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 42
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR FELINES
 
 
 
 
TABLE 43
VETERINARY BIOLOGICS MARKET FOR FELINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 44
VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 45
VETERINARY BIOLOGICS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 46
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR BOVINES
 
 
 
 
TABLE 47
VETERINARY BIOLOGICS MARKET FOR BOVINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 48
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR SMALL RUMINANTS
 
 
 
 
TABLE 49
VETERINARY BIOLOGICS MARKET FOR SMALL RUMINANT, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 50
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR PORCINES
 
 
 
 
TABLE 51
VETERINARY BIOLOGICS MARKET FOR PORCINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 52
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR POULTRY
 
 
 
 
TABLE 53
VETERINARY BIOLOGICS MARKET FOR POULTRY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 54
KEY PLAYERS PROVIDING VETERINARY BIOLOGICS FOR EQUINES
 
 
 
 
TABLE 55
VETERINARY BIOLOGICS MARKET FOR EQUINE, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 56
VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 57
VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 58
VETERINARY BIOLOGICS MARKET FOR INJECTABLE ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 59
VETERINARY BIOLOGICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 60
VETERINARY BIOLOGICS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 61
VETERINARY BIOLOGICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 62
VETERINARY BIOLOGICS MARKET FOR OTHER INJECTABLE ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 63
VETERINARY BIOLOGICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 64
VETERINARY BIOLOGICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 65
VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 66
VETERINARY BIOLOGICS MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 67
VETERINARY BIOLOGICS MARKET FOR DIAGNOSTIC TESTNG, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 68
VETERINARY BIOLOGICS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 69
VETERINARY BIOLOGICS MARKET FOR INFECTIOUS DISEASE PREVENTION, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 70
VETERINARY BIOLOGICS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 71
VETERINARY BIOLOGICS MARKET FOR OTHER APPLICATIONS,BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 72
VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 73
AVERAGE TOTAL AMOUNT SPENT PER HOUSEHOLD ON PETS IN US, 2023–2024 (USD)
 
 
 
 
TABLE 74
VETERINARY BIOLOGICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 75
VETERINARY BIOLOGICS MARKET FOR VETERINARY DIAGNOSTIC LABS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 76
VETERINARY BIOLOGICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 77
VETERINARY BIOLOGICS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 78
VETERINARY BIOLOGICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (THOUSAND UNITS)
 
 
 
 
TABLE 79
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY 2023–2030 (USD MILLION
 
 
 
 
TABLE 80
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 81
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 82
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 83
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 84
NORTH AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 85
US: KEY MACROINDICATORS
 
 
 
 
TABLE 86
US: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 87
US: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 88
US: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 89
US: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 90
US: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 91
CANADA: KEY MACROINDICATORS
 
 
 
 
TABLE 92
CANADA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 93
CANADA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 94
CANADA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 95
CANADA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 96
CANADA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 97
EUROPE: VETERINARY BIOLOGICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION
 
 
 
 
TABLE 98
EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 99
EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 100
EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 101
EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 102
EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 103
GERMANY: KEY MACROINDICATORS
 
 
 
 
TABLE 104
GERMANY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 105
GERMANY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 106
GERMANY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 107
GERMANY: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 108
GERMANY: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 109
UK: KEY MACROINDICATORS
 
 
 
 
TABLE 110
UK: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 111
UK: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 112
UK: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 113
UK: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 114
UK: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 115
FRANCE: KEY MACROINDICATORS
 
 
 
 
TABLE 116
FRANCE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 117
FRANCE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 118
FRANCE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 119
FRANCE: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 120
FRANCE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 121
ITALY: KEY MACROINDICATORS
 
 
 
 
TABLE 122
ITALY: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 123
ITALY: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 124
ITALY: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 125
ITALY: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 126
ITALY: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 127
SPAIN: KEY MACROINDICATORS
 
 
 
 
TABLE 128
SPAIN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 129
SPAIN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 130
SPAIN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 131
SPAIN: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 132
SPAIN: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 133
NETHERLANDS: KEY MACROINDICATORS
 
 
 
 
TABLE 134
NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 135
NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 136
NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 137
NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 138
NETHERLANDS: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 139
REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 140
REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 141
REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 142
REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 143
REST OF EUROPE: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 144
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY COUNTRY 2023–2030 (USD MILLION
 
 
 
 
TABLE 145
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 146
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 147
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 148
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 149
ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 150
JAPAN: KEY MACROINDICATORS
 
 
 
 
TABLE 151
JAPAN: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 152
JAPAN: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 153
JAPAN: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 154
JAPAN: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 155
JAPAN: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 156
CHINA: KEY MACROINDICATORS
 
 
 
 
TABLE 157
CHINA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 158
CHINA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 159
CHINA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 160
CHINA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 161
CHINA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 162
INDIA: PRODUCTION AND CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2000 VS. 2030 (THOUSAND METRIC TONS)
 
 
 
 
TABLE 163
INDIA: KEY MACROINDICATORS
 
 
 
 
TABLE 164
INDIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 165
INDIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 166
INDIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 167
INDIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 168
INDIA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 169
AUSTRALIA: KEY MACROINDICATORS
 
 
 
 
TABLE 170
AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 171
AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 172
AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 173
AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 174
AUSTRALIA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 175
SOUTH KOREA: KEY MACROINDICATORS
 
 
 
 
TABLE 176
SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 177
SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 178
SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 179
SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 180
SOUTH KOREA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 181
NEW ZEALAND: KEY MACROINDICATORS
 
 
 
 
TABLE 182
NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 183
NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 184
NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 185
NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 186
NEW ZEALAND: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 187
REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 188
REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 189
REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 190
REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 191
REST OF ASIA PACIFIC: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 192
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION
 
 
 
 
TABLE 193
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 194
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 195
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 196
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 197
LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 198
BRAZIL: KEY MACROINDICATORS
 
 
 
 
TABLE 199
BRAZIL: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 200
BRAZIL: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 201
BRAZIL: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 202
BRAZIL: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 203
BRAZIL: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 204
MEXICO: KEY MACROINDICATORS
 
 
 
 
TABLE 205
MEXICO: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 206
MEXICO: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 207
MEXICO: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 208
MEXICO: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 209
MEXICO: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 210
REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 211
REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 212
REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 213
REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 214
REST OF LATIN AMERICA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 215
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY REGION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 216
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 217
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 218
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 219
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 220
MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 221
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 222
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 223
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 224
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 225
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 226
GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 227
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
 
 
 
 
TABLE 228
KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 229
KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 230
KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 231
KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 232
KINGDOM OF SAUDI ARABIA (KSA): VETERINARY BIOLOGICS MARKET,BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 233
UNITED ARAB EMIRATES (UAE): KEY MACROINDICATORS
 
 
 
 
TABLE 234
UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 235
UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 236
UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 237
UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 238
UNITED ARAB EMIRATES (UAE): VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 239
REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 240
REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 241
REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 242
REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 243
REST OF GCC COUNTRIES: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 244
REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 245
REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 246
REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 247
REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 248
REST OF MIDDLE EAST & AFRICA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030 (USD MILLION)
 
 
 
 
TABLE 249
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN VETERINARY BIOLOGICS MARKET
 
 
 
 
TABLE 250
VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024
 
 
 
 
TABLE 251
VETERINARY BIOLOGICS MARKET: DEGREE OF COMPETITION, 2024
 
 
 
 
TABLE 252
VETERINARY DIAGNOSTIC KITS MARKET: DEGREE OF COMPETITION, 2024
 
 
 
 
TABLE 254
VETERINARY BIOLOGICS MARKET: REGION FOOTPRINT
 
 
 
 
TABLE 255
VETERINARY BIOLOGICS MARKET: PRODUCT TYPE FOOTPRINT
 
 
 
 
TABLE 256
VETERINARY BIOLOGICS MARKET: ANIMAL TYPE FOOTPRINT
 
 
 
 
TABLE 257
VETERINARY BIOLOGICS MARKET: APPLICATION FOOTPRINT
 
 
 
 
TABLE 258
VETERINARY BIOLOGICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
 
 
 
 
TABLE 259
VETERINARY BIOLOGICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY ANIMAL TYPE AND REGION
 
 
 
 
TABLE 260
VETERINARY BIOLOGICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 261
VETERINARY BIOLOGICS MARKET: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 262
VETERINARY BIOLOGICS MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 263
VETERINARY BIOLOGICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 264
ZOETIS SERVICES LLC: COMPANY OVERVIEW
 
 
 
 
TABLE 265
ZOETIS SERVICES LLC: PRODUCTS OFFERED
 
 
 
 
TABLE 266
ZOETIS SERVICES LLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 267
ZOETIS SERVICES LLC: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 268
ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 269
ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 270
IDEXX: COMPANY OVERVIEW
 
 
 
 
TABLE 271
IDEXX: PRODUCTS OFFERED
 
 
 
 
TABLE 272
IDEXX: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 273
ELANCO: COMPANY OVERVIEW
 
 
 
 
TABLE 274
ELANCO: PRODUCTS OFFERED
 
 
 
 
TABLE 275
ELANCO: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 276
ELANCO: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 277
ELANCO: EXPANSIONS, JANUARY 2022−AUGUST 2025
 
 
 
 
TABLE 278
MERCK & CO., INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 279
MERCK & CO., INC.: PRODUCTS OFFERED
 
 
 
 
TABLE 280
MERCK & CO., INC.: PRODUCT LAUNCHES, JANUARY 2022−AUGUST 2025
 
 
 
 
TABLE 281
MERCK & CO., INC.: EXPANSIONS, JANUARY 2022−AUGUST 2025
 
 
 
 
TABLE 282
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 283
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
 
 
 
 
TABLE 284
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
 
 
 
 
TABLE 285
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
 
 
 
 
TABLE 286
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 287
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 288
NEOGEN CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 289
NEOGEN CORPORATION: PRODUCTS OFFERED
 
 
 
 
TABLE 290
NEOGEN CORPORATION: DEALS, JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 291
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 292
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
 
 
 
 
TABLE 293
IMMUCELL CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 294
IMMUCELL CORPORATION: PRODUCTS OFFERED
 
 
 
 
TABLE 295
IMMUCELL CORPORATION: OTHER DEVELOPMENTS,JANUARY 2022–AUGUST 2025
 
 
 
 
TABLE 296
INNOVATIVE DIAGNOSTICS: COMPANY OVERVIEW
 
 
 
 
TABLE 297
INNOVATIVE DIAGNOSTICS: PRODUCTS OFFERED
 
 
 
 
TABLE 298
BIONOTE USA INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 299
BIOCHECK: COMPANY OVERVIEW
 
 
 
 
TABLE 300
PLASVACC USA: COMPANY OVERVIEW
 
 
 
 
TABLE 301
NOVAVIVE INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 302
MG BIOLOGICS: COMPANY OVERVIEW
 
 
 
 
TABLE 303
STALLERGENES GREER: COMPANY OVERVIEW
 
 
 
 
TABLE 304
BIOSTONE ANIMAL HEALTH: COMPANY OVERVIEW
 
 
 
 
TABLE 305
COLORADO SERUM COMPANY: COMPANY OVERVIEW
 
 
 
 
TABLE 306
PADULA SERUMS PTY LTD.: COMPANY OVERVIEW
 
 
 
 
TABLE 307
LAKE IMMUNOGENICS: COMPANY OVERVIEW
 
 
 
 
TABLE 308
INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 309
PRINCETON BIOMEDITECH CORPORATION: COMPANY OVERVIEW
 
 
 
 
TABLE 310
TETRACORE, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 311
VMRD, INC.: COMPANY OVERVIEW
 
 
 
 
TABLE 312
ANIMAB: COMPANY OVERVIEW
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
FIGURE 1
VETERINARY BIOLOGICS MARKET SEGMENTATION & REGIONAL SCOPE
 
 
 
 
FIGURE 2
VETERINARY BIOLOGICS MARKET: YEARS CONSIDERED
 
 
 
 
FIGURE 3
VETERINARY BIOLOGICS MARKET: RESEARCH DESIGN
 
 
 
 
FIGURE 4
VETERINARY BIOLOGICS MARKET: KEY DATA FROM SECONDARY SOURCES
 
 
 
 
FIGURE 5
VETERINARY BIOLOGICS MARKET: KEY PRIMARY SOURCES
 
 
 
 
FIGURE 6
VETERINARY BIOLOGICS MARKET: INSIGHTS FROM KEY PRIMARIES
 
 
 
 
FIGURE 7
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
 
 
 
 
FIGURE 8
BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
 
 
 
 
FIGURE 9
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
 
 
 
 
FIGURE 10
VETERINARY BIOLOGICS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)
 
 
 
 
FIGURE 11
VETERINARY BIOLOGICS MARKET SIZE ESTIMATION
 
 
 
 
FIGURE 12
VETERINARY BIOLOGICS MARKET: TOP-DOWN APPROACH
 
 
 
 
FIGURE 13
VETERINARY BIOLOGICS MARKET: BOTTOM-UP APPROACH
 
 
 
 
FIGURE 14
VETERINARY BIOLOGICS MARKET: CAGR PROJECTIONS
 
 
 
 
FIGURE 15
VETERINARY BIOLOGICS MARKET: DATA TRIANGULATION METHODOLOGY
 
 
 
 
FIGURE 16
VETERINARY BIOLOGICS MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 17
VETERINARY BIOLOGICS MARKET, BY ANIMAL TYPE, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 18
VETERINARY BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 19
VETERINARY BIOLOGICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 20
VETERINARY BIOLOGICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
 
 
 
 
FIGURE 21
GEOGRAPHICAL SNAPSHOT OF VETERINARY BIOLOGICS MARKET
 
 
 
 
FIGURE 22
INCREASING PREVALENCE OF CHRONIC DISEASES AMONG COMPANION ANIMALS TO DRIVE MARKET
 
 
 
 
FIGURE 23
US AND COMPANION ANIMALS COMMANDED LARGEST NORTH AMERICAN VETERINARY BIOLOGICS MARKET SHARE IN 2024
 
 
 
 
FIGURE 24
MONOCLONAL ANTIBODIES CAPTURED LARGEST SHARE DURING FORECAST PERIOD
 
 
 
 
FIGURE 25
COMPANION ANIMALS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030
 
 
 
 
FIGURE 26
INJECTABLE ROUTE OF ADMINISTRATION TO DOMINATE MARKET IN 2030
 
 
 
 
FIGURE 27
DERMATOLOGY TO LEAD VETERINARY BIOLOGICS MARKET IN 2030
 
 
 
 
FIGURE 28
US TO REGISTER HIGHEST GROWTH IN VETERINARY BIOLOGICS MARKET FROM 2025 TO 2030
 
 
 
 
FIGURE 29
VETERINARY BIOLOGICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
FIGURE 30
VETERINARY BIOLOGICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
FIGURE 31
VETERINARY BIOLOGICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
FIGURE 32
VETERINARY BIOLOGICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
FIGURE 33
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
 
 
 
 
FIGURE 34
KEY BUYING CRITERIA FOR MAJOR END USERS
 
 
 
 
FIGURE 35
PATENT ANALYSIS FOR VETERINARY MONOCLONAL ANTIBODIES IN VETERINARY BIOLOGICS MARKET, JANUARY 2014–AUGUST 2025
 
 
 
 
FIGURE 36
TOP APPLICANT COUNTRIES AND NUMBER OF PATENT APPLICANTS FOR VETERINARY MONOCLONAL ANTIBODIES, BY JURISDICTION, JANUARY 2014–AUGUST 2025
 
 
 
 
FIGURE 37
VETERINARY BIOLOGICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
FIGURE 38
KEY AI USE CASES IN VETERINARY BIOLOGICS MARKET
 
 
 
 
FIGURE 39
FUNDING AND NUMBER OF DEALS IN VETERINARY BIOLOGICS MARKET, 2020–2024 (USD MILLION)
 
 
 
 
FIGURE 40
NORTH AMERICA: VETERINARY BIOLOGICS MARKET SNAPSHOT
 
 
 
 
FIGURE 41
REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET, 2022–2024
 
 
 
 
FIGURE 42
MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024)
 
 
 
 
FIGURE 43
US MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024)
 
 
 
 
FIGURE 44
MARKET SHARE ANALYSIS OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024)
 
 
 
 
FIGURE 45
US: VETERINARY DIAGNOSTIC KITS MARKET SHARE ANALYSIS, 2024
 
 
 
 
FIGURE 46
RANKING OF KEY PLAYERS IN VETERINARY BIOLOGICS MARKET (2024)
 
 
 
 
FIGURE 47
RANKING OF KEY PLAYERS IN VETERINARY DIAGNOSTIC KITS MARKET (2024)
 
 
 
 
FIGURE 48
VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX, 2024
 
 
 
 
FIGURE 49
VETERINARY BIOLOGICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
 
 
 
 
FIGURE 50
VETERINARY BIOLOGICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
 
 
 
 
FIGURE 51
EV/EBITDA OF KEY VENDORS
 
 
 
 
FIGURE 52
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
FIGURE 53
ZOETIS SERVICES LLC: COMPANY SNAPSHOT
 
 
 
 
FIGURE 54
IDEXX: COMPANY SNAPSHOT
 
 
 
 
FIGURE 55
ELANCO: COMPANY SNAPSHOT
 
 
 
 
FIGURE 56
MERCK & CO., INC.: COMPANY SNAPSHOT
 
 
 
 
FIGURE 57
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
 
 
 
 
FIGURE 58
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
 
 
 
 
FIGURE 59
NEOGEN CORPORATION: COMPANY SNAPSHOT
 
 
 
 
FIGURE 60
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
 
 
 
 
FIGURE 61
IMMUCELL CORPORATION: COMPANY SNAPSHOT
 
 
 
 

Methodology

This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

Secondary Research

This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

A breakdown of the primary respondents is provided below:

Veterinary Biologics Market

Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

Veterinary Biologics Market

Data Triangulation

After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

Market Definition

The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

Stakeholders

  • Veterinary Biologics Manufacturers
  • Animal Healthcare Product Manufacturers
  • Veterinary Biologics Distributors and Wholesalers
  • Animal Welfare Associations
  • Veterinary Clinics and Care Centers
  • Research And Consulting Firms
  • Veterinary Research and Development Organizations
  • Contract Manufacturing Organizations
  • Venture Capitalists

Report Objectives

  • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
  • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
  • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

 

TABLE OF CONTENTS

METHODOLOGY

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Veterinary Biologics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Veterinary Biologics Market

DMCA.com Protection Status